Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) EBT Margin (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of EBT Margin readings, the most recent being 1.59% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 120.0% to 1.59% in Q1 2026 year-over-year; TTM through Jan 2026 was 0.76%, a 432.0% increase, with the full-year FY2025 number at 1.05%, up 690.0% from a year prior.
  • EBT Margin hit 1.59% in Q1 2026 for Pharma-Bio Serv, up from 0.2% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 13.57% in Q1 2023 to a low of 12.0% in Q3 2024.
  • Median EBT Margin over the past 5 years was 1.59% (2026), compared with a mean of 1.54%.
  • The widest YoY moves for EBT Margin: up 9068bps in 2022, down -3976bps in 2022.
  • Pharma-Bio Serv's EBT Margin stood at 4.98% in 2022, then crashed by -127bps to 1.33% in 2023, then skyrocketed by 52bps to 0.64% in 2024, then surged by 131bps to 0.2% in 2025, then surged by 703bps to 1.59% in 2026.
  • The last three reported values for EBT Margin were 1.59% (Q1 2026), 0.2% (Q4 2025), and 10.65% (Q3 2025) per Business Quant data.